ARTICLE | Clinical News
Humira adalimumab: Phase II; marketed for rheumatoid arthritis (RA) in
February 16, 2004 8:00 AM UTC
In a double-blind, North American Phase II trial in 148 patients, 53% of those receiving Humira 40 mg every other week and 80% of patients receiving Humira 40 mg weekly had a PASI 75 response, compare...